Wound disinfecting and repairing agent containing modified chitosan and preparation method of wound disinfecting and repairing agent

Abstract

The invention discloses a wound disinfecting and repairing agent containing modified chitosan and a preparation method of the wound disinfecting and repairing agent, and belongs to the technical field of wound disinfecting and repairing agents, the composite wound disinfecting and repairing agent comprises the following components in percentage by mass: 3-10% of organic acid, 1-30% of chitosan, 2-20% of benzalkonium bromide, 1-10% of liposome solution and the balance of water; the preparation method of the wound disinfecting and repairing agent comprises the following steps: dissolving organic acid in water to obtain an acidic solution; adding chitosan into the acid solution, and stirring until the chitosan is completely homogenized; preparing a lipidosome solution in a manner of assisting lipidosome preparation by an electric field; mixing the liposome solution and the chitosan solution, adding benzalkonium bromide, and uniformly mixing; and separating out a chitosan solution with the molecular weight of more than 100,000 in the solution by using an ultrafiltration tube, and re-dissolving by using normal saline to obtain the chitosan solution. The efficiency of adsorbing bacteria by the chitosan can be greatly improved, so that the antibacterial ability is improved, and meanwhile, the inflammatory response can be quickly reduced and wound scabbing and repairing can be accelerated.

Description

Technical Field

[0001] The present invention relates to the technical field of wound disinfecting and repairing agents, and in particular to a composite wound disinfecting and repairing agent containing modified chitosan and a preparation method thereof. Background Art

[0002] Wound repair agents are a class of biomaterials or chemicals used to promote wound healing, reduce scarring, and prevent infection. They are widely used in the medical field, including surgery, burn treatment, and chronic wound care. In recent years, with the advancement of biomedical technology, the variety and functions of wound repair agents have continued to expand, from traditional gauze dressings to modern bioactive materials such as epidermal growth factor (EGF), hyaluronic acid, and chitosan. For example, EGF is a small molecule protein that stimulates the proliferation and differentiation of epidermal cells, accelerating the wound healing process. It is widely used clinically to treat wounds such as burns and ulcers. Hyaluronic acid, due to its excellent moisture retention and biocompatibility, is used in wound dressings to maintain wound moisture and promote healing. Furthermore, chitosan, a natural polymer material, has also attracted widespread attention in the wound repair field due to its unique bioactivity and biodegradability.

[0003] Chitosan is a natural polymer material extracted from chitin in shrimp and crabs. It has good biocompatibility, antibacterial properties, and biodegradability. The application of chitosan in wound repair is mainly reflected in the following aspects: 1. Wound Dressing: Chitosan can be made into a film or sponge dressing that absorbs wound exudate while providing a moist environment and accelerating wound healing. Its antibacterial properties can also effectively reduce the risk of wound infection.

[0004] 2. Surgery: Chitosan can be used to prepare absorbable surgical sutures, reducing postoperative infection and tissue reactions. In addition, chitosan can also be used as a tissue engineering scaffold material to promote tissue regeneration.

[0005] 3. Drug Carrier: Chitosan can be used as a drug carrier in the preparation of sustained-release pharmaceutical formulations. It can encapsulate drug molecules, control the release rate, and improve drug stability and bioavailability. For example, during wound healing, chitosan can carry growth factors, promoting rapid wound healing.

[0006] However, chitosan also has some shortcomings in wound repair applications. First, chitosan's poor solubility limits its use in certain applications. Second, chitosan's antimicrobial effect is relatively weak, with limited ability to inhibit certain drug-resistant bacteria. Furthermore, chitosan's mechanical properties need to be improved to better meet the requirements of surgical procedures and wound dressings.

[0007] In view of the limitations of existing wound repair agents in promoting wound healing and antibacterial properties, as well as the shortcomings of chitosan in these aspects, the present invention aims to develop a new type of high-efficiency wound repair material. By combining the natural properties of chitosan with the performance of other advanced materials, the defects of existing materials are overcome to achieve rapid, efficient and safe wound healing effects, while reducing the cost of use and improving the stability and practicality of the material. Summary of the Invention

[0008] The present invention provides a wound disinfection and repair agent containing modified chitosan and a preparation method thereof, so as to solve the limitations of chitosan in promoting wound healing and having antibacterial properties when used as a wound repair agent.

[0009] In order to solve the above technical problems, the technical solution of the present invention is: A wound disinfecting and repairing agent containing modified chitosan comprises, by mass percentage, 3-10% of organic acid, 1-30% of chitosan, 2-20% of benzalkonium bromide, 1-10% of liposome solution, and the balance being water.

[0010] The organic acid is any one or more of formic acid, benzoic acid, acetic acid, propionic acid, butyric acid, succinic acid, valeric acid, tartaric acid, oxalic acid, ascorbic acid, malic acid, citric acid, lactic acid, salicylic acid, and caffeic acid.

[0011] A method for preparing a wound disinfectant and repairing agent containing modified chitosan comprises the following steps: (1) Dissolve the organic acid in water to obtain an acidic solution; (2) Add chitosan to the acidic solution and stir at room temperature for 1-5 hours until completely homogenized; (3) preparing liposome solution by electric field-assisted liposome preparation; (4) Mix the liposome solution and chitosan solution, stir slowly at 20-80°C for 1-6 hours, add benzalkonium bromide during the process, and mix well; (5) Use a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000, and then re-dissolve it with physiological saline.

[0012] Wherein, step (3) specifically includes the following steps: (1) Dissolve phosphatidylcholine and cholesterol in a chloroform:methanol mixed solution to form a homogeneous liposome solution, then place the liposome solution in an evaporation tube container, and dry the liposome solution by rotary evaporation to form a thin film in the evaporation tube; (2) Add physiological saline to the evaporating tube and slowly stir at 37°C for 1-3 hours to redisperse the lipids into liposomes; (3) Placing the liposome suspension in an electric field device, using an AC electric field with electric field parameters of 1-100 kV / m, 1-500 kHz, and 1-100 minutes. Under the action of the electric field, the lipid molecules will rearrange to form multilamellar liposomes; (4) Use an ultrasonic processor to emulsify the multilayer liposome solution. The ultrasonic processor power needs to be between 100-1000W, the frequency needs to be 1-100 kHz, and the process needs to be performed at room temperature for 1-5 hours. The purpose is to adjust the liposome particle size to the target range, which is 10-1000 nm.

[0013] (5) Using dialysis for purification, the electric field-assisted liposome preparation is completed.

[0014] Wherein, in step (1), the mass percentage of phosphatidylcholine in the homogeneous liposome solution is 1-10%, the mass percentage of cholesterol is 2-20%, and the volume ratio of chloroform to methanol in the chloroform:methanol mixed solution is 2:1.

[0015] In step (2), the volume of the physiological saline added is the same as the volume of the chloroform:methanol mixed solution in step (1).

[0016] Wherein, in step (5), dialysis is specifically as follows: placing the liposome solution into a dialysis bag, and then placing more than 1000 times the volume of physiological saline.

[0017] Compared with the prior art, the present invention has the following beneficial effects: The chitosan in this invention carries a positive charge. By virtue of the principle of attraction between positive and negative charges, chitosan rapidly absorbs negatively charged airborne molecules such as bacteria and viruses, significantly increasing its sterilization and disinfection capabilities. Chitosan can also replace the cellular matrix during wound repair, accelerating the formation of scab tissue.

[0018] The present invention adds any one or more of formic acid, benzoic acid, acetic acid, propionic acid, butyric acid, succinic acid, valeric acid, tartaric acid, oxalic acid, ascorbic acid, malic acid, citric acid, lactic acid, salicylic acid, and caffeic acid. The addition of the acid increases the activity and fluidity of the chitosan molecules in the solution. Since different acids have different rates of dissociating hydrogen ions, adding multiple mixed acids has the best effect.

[0019] The present invention adds benzalkonium bromide, which is a positively charged molecule. The purpose of adding benzalkonium bromide is to increase the number of positive charges on chitosan, modify the chitosan, and further improve the adsorption capacity of chitosan. Benzalkonium bromide also has a bactericidal effect and can enhance the bactericidal effect of chitosan.

[0020] The present invention uses an ultrafiltration tube to collect chitosan solution with a molecular weight of more than 100,000 because chitosan with a molecular weight greater than 50,000-100,000 has higher viscosity and film-forming properties and can easily form a thicker film on the wound surface. This method can accelerate the anaerobic state of the wound and the speed of wound scab repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The drawings in the specification, which constitute a part of this application, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0022] Figure 1 Rat wound area and rat wound healing rate curve. DETAILED DESCRIPTION

[0023] The following will be combined with specific embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention. Example 1

[0024] This embodiment provides a wound disinfectant and repairing agent containing modified chitosan, which comprises, by mass percentage, 2% acetic acid, 2% malic acid, 2% citric acid, 15% chitosan, 12% benzalkonium bromide, 5% liposome solution, and the balance is water.

[0025] This embodiment also provides a method for preparing the wound disinfectant and repair agent containing modified chitosan, comprising the following steps: (1) Dissolve acetic acid, malic acid, and citric acid in water to obtain an acidic solution; (2) Add chitosan to the acidic solution and stir at room temperature for 1-5 hours until completely homogenized; (3) preparing liposome solution by electric field-assisted liposome preparation; (4) Mix the liposome solution and chitosan solution, stir slowly at 50°C for 3 hours, add benzalkonium bromide during the process, and mix well; (5) Use a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000, and then re-dissolve it with physiological saline.

[0026] Wherein, step (3) specifically includes the following steps: (1) Dissolve phosphatidylcholine and cholesterol in a chloroform:methanol mixed solution with a volume ratio of 2:1 to form a homogeneous liposome solution, wherein the mass percentage of phosphatidylcholine in the homogeneous liposome solution is 5% and the mass percentage of cholesterol is 10%. Then, place the liposome solution in an evaporation tube container and dry the liposome solution by rotary evaporation to form a thin film in the evaporation tube; (2) Add physiological saline to the evaporating tube. The volume of the added physiological saline is the same as that of the chloroform:methanol mixed solution in step (1). Stir slowly at 37°C for 2 hours to redisperse the lipids into liposomes. (3) The liposome suspension is placed in an electric field device, using an AC electric field with the electric field parameters of 50 kV / m, 250 kHz, and a treatment time of 50 minutes. Under the action of the electric field, the lipid molecules will rearrange to form multilamellar liposomes; (4) Emulsify the multilamellar liposome solution using an ultrasonic processor with a power of 500 W, a frequency of 50 kHz, at room temperature for 3 hours to adjust the liposome particle size to the target range of 500 nm. (5) The liposome solution is placed in a dialysis bag, and then 1000 times the volume of normal saline is added to purify it using dialysis, thus completing the electric field-assisted liposome preparation. Example 2

[0027] This embodiment provides a wound disinfecting and repairing agent containing modified chitosan, which comprises, by mass percentage, 1% benzoic acid, 1% oxalic acid, 1% malic acid, 30% chitosan, 2% benzalkonium bromide, 10% liposome solution, and the balance water.

[0028] This embodiment also provides a method for preparing the wound disinfectant and repair agent containing modified chitosan, comprising the following steps: (1) Dissolve benzoic acid, oxalic acid and malic acid in water to obtain an acidic solution; (2) Add chitosan to the acidic solution and stir at room temperature for 1-5 hours until completely homogenized; (3) preparing liposome solution by electric field-assisted liposome preparation; (4) Mix the liposome solution and chitosan solution, stir slowly at 20°C for 6 hours, add benzalkonium bromide during the process, and mix well; (5) Use a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000, and then re-dissolve it with physiological saline.

[0029] Wherein, step (3) specifically includes the following steps: (1) Dissolve phosphatidylcholine and cholesterol in a chloroform:methanol mixed solution with a volume ratio of 2:1 to form a homogeneous liposome solution, wherein the mass percentage of phosphatidylcholine is 1% and the mass percentage of cholesterol is 20%. Then, place the liposome solution in an evaporation tube container, and dry the liposome solution by rotary evaporation to form a thin film in the evaporation tube; (2) Add physiological saline to the evaporating tube. The volume of the added physiological saline is the same as that of the chloroform:methanol mixed solution in step (1). Stir slowly at 37°C for 1 hour to redisperse the lipids into liposomes. (3) The liposome suspension is placed in an electric field device, using an AC electric field with the electric field parameters of 1 kV / m, 1 kHz, and a treatment time of 100 minutes. Under the action of the electric field, the lipid molecules will rearrange to form multilayer liposomes; (4) Emulsify the multi-layer liposome solution using an ultrasonic processor with a power of 100 W, a frequency of 1 kHz, at room temperature, for 5 hours to adjust the liposome particle size to the target range of 1000 nm. (5) The liposome solution is placed in a dialysis bag, and then 1000 times the volume of normal saline is added to purify it using dialysis, thus completing the electric field-assisted liposome preparation. Example 3

[0030] This embodiment provides a wound disinfectant and repair agent containing modified chitosan, which comprises, by mass percentage, 2% formic acid, 3% succinic acid, 3% ascorbic acid, 2% salicylic acid, 1% chitosan, 20% benzalkonium bromide, 1% liposome solution, and the balance is water.

[0031] This embodiment also provides a method for preparing the wound disinfectant and repair agent containing modified chitosan, comprising the following steps: (1) Dissolve formic acid, succinic acid, ascorbic acid and salicylic acid in water to obtain an acidic solution; (2) Add chitosan to the acidic solution and stir at room temperature for 1-5 hours until completely homogenized; (3) preparing liposome solution by electric field-assisted liposome preparation; (4) Mix the liposome solution and chitosan solution, stir slowly at 20-80°C for 1-6 hours, add benzalkonium bromide during the process, and mix well; (5) Use a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000, and then re-dissolve it with physiological saline.

[0032] Wherein, step (3) specifically includes the following steps: (1) Dissolve phosphatidylcholine and cholesterol in a chloroform:methanol mixed solution with a volume ratio of 2:1 to form a homogeneous liposome solution, wherein the mass percentage of phosphatidylcholine in the homogeneous liposome solution is 10% and the mass percentage of cholesterol is 2%. Then, place the liposome solution in an evaporation tube container and dry the liposome solution by rotary evaporation to form a thin film in the evaporation tube; (2) Add physiological saline to the evaporating tube. The volume of the added physiological saline is the same as that of the chloroform:methanol mixed solution in step (1). Stir slowly at 37°C for 3 hours to redisperse the lipids into liposomes. (3) The liposome suspension is placed in an electric field device, using an AC electric field with the following parameters: voltage 100 kV / m, frequency 500 kHz, and treatment time 1 minute. Under the action of the electric field, the lipid molecules will rearrange to form multilamellar liposomes; (4) Emulsify the multi-layer liposome solution using an ultrasonic processor. The ultrasonic processor power needs to be between 1000 W and the frequency needs to be 100 kHz. The operation time should be 1 hour at room temperature. The purpose is to adjust the liposome particle size to the target range, which is 10 nm. (5) The liposome solution is placed in a dialysis bag, and then 1000 times the volume of normal saline is added to purify it using dialysis, thus completing the electric field-assisted liposome preparation.

[0033] Comparative Example 1 This embodiment provides a wound disinfectant and repair agent containing modified chitosan. The preparation method of this embodiment does not include step (5), that is, there is no step of "using a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000 in the solution, and then re-dissolving it with physiological saline." The rest is the same as in Example 1.

[0034] Comparative Example 2 This embodiment provides a wound disinfecting and repairing agent containing modified chitosan. Only acetic acid is added to the wound disinfecting and repairing agent to prepare an acidic solution. The amounts of other substances and the preparation method are the same as those in Example 1.

[0035] Comparative Example 3 This embodiment provides a wound disinfecting and repairing agent containing modified chitosan. Benzalkonium bromide is not added to the wound disinfecting and repairing agent, and the amounts of other substances and the preparation method are the same as those in Example 1.

[0036] Comparative Example 4 This embodiment provides a wound disinfectant and repair agent containing modified chitosan. In the preparation method of the liposome solution of the wound disinfectant and repair agent, phosphatidylcholine and cholesterol are dissolved in a chloroform:methanol mixed solution (the ratio of chloroform to methanol is 2:1), without using an electric field assist, and the amounts of other substances and the preparation method are the same as in Example 1.

[0037] Antibacterial test

[0038] Materials and Methods 1.1 Reagents Wound disinfection and repairing agent: the wound disinfection and repairing agent prepared in Examples 1-3 and the wound disinfection and repairing agent prepared in Comparative Examples 1-4, strain: Escherichia coli field isolate.

[0039] Testing unit: Henan Agricultural University Animal Disease Testing and Diagnosis Center.

[0040] 1.2 Method 1 (refer to the minimum inhibitory concentration MIC test method) Since chitosan can only show its antibacterial effect in acidic conditions, the antibacterial effect is not tested by the traditional plate-coating method, but by an experimental method called MIC (minimum inhibitory concentration). After culturing bacteria in acidic broth, the bacterial concentration is read by absorbance.

[0041] 1.2.1 Operation steps Use a hanging bacteria loop to scrape the tops of 3 to 4 single colonies from the culture plate and inoculate them into CAMHB or LB broth at 37°C with shaking at 220 rpm for 8 to 12 hours. When the OD620 value of the bacterial solution is between 0.08 and 0.13 (i.e., the bacterial solution concentration is about 1x10 8 cfu / mL), dilute the bacterial solution with CAMHB or LB broth at a ratio of 1:100 (i.e., the bacterial solution concentration is about 1x10 6 cfu / mL), and the diluted bacterial solution was used for drug sensitivity test (used within 20 minutes).

[0042] The experiment should be divided into three groups: positive control group, negative control group, test sample group Positive control group: 10 6 cfu / mL bacterial solution, take 2uL and add 200uL CAMHB broth to make the bacterial solution concentration 10 4 cfu / mL, and measure the OD620 value after 18-24 hours of incubation. The incubation time is recommended to be based on the time when the bacterial count in the positive control group is saturated.

[0043] Negative control group: Take 200uL of broth containing the test sample and culture for 18-24h before measuring the OD620 value.

[0044] Test sample group: dilute the test sample according to the required concentration, add the sample to the broth to make the total volume 200uL, 10 6 Take 2uL of bacterial solution and add 200uL of broth containing the sample to make the bacterial solution concentration 10 4cfu / mL, and the OD620 value was measured after 18-24 hours of incubation. The inhibition rate was calculated based on the average OD value of four replicates, with a tolerance of 15% between groups.

[0045] 1.2.2 Operation Layout React according to the sample distribution in the table below

[0046] 1.2.3 Measurement methods of bacterial solution concentration and inhibition rate After adding the bacterial solution, measure the OD620 using an ELISA plate reader. After incubating in the incubator for 24 hours, measure the OD620 again using the ELISA plate reader. Compare the OD value with that of the positive control group to determine the relative inhibition rate. The calculation formula is as follows:

[0047] 2.1 MIC method results

[0048] The above data show that the wound disinfectant and repairing agents of Examples 1, 2, and 3 of the present invention have an antibacterial activity of 98.40-99.60% against Escherichia coli after being diluted 250-fold. Furthermore, the comparative data show that not using an ultrafiltration tube for separation, adding only acetic acid, not adding benzalkonium bromide, and not using an electric field to assist in preparing the liposome solution all significantly affect the antibacterial activity of the wound disinfectant and repairing agents.

[0049] Wound healing assay

[0050] 1 Materials and Methods

[0051] 1.1 Reagents 1.1.1 Experimental animals: 25 female Sprague-Dawley rats aged 6-20 weeks and weighing more than 250 g 1.1.2 Related reagents: modified chitosan wound disinfectant and repair agent (Formula 1, Formula 2), erythromycin ointment, medical recombinant type III humanized collagen repair gel (EGF), Shutai anesthetic, ibuprofen syrup, 75% alcohol, etc.

[0052] 1.1.3 Related tools: mouse cage, waterer, hole punch, vernier caliper, surgical scissors, tweezers, 1 mL syringe, alcohol cotton balls, shaver, etc.

[0053] 1.2 Methods 1.2.1 Operation steps 1.2.1.1 Animal Grouping Twenty-five female SD mice were randomly divided into five groups, with five mice in each group, and named as formula group 1, formula group 2, erythromycin group, EGF group and negative control group respectively.

[0054] 1.2.1.2 Preoperative management Use commercially available ibuprofen syrup, mix it into drinking water, and use a low dose (about 2.1 ml of syrup mixed with 500 ml of drinking water) 24 hours before surgery.

[0055] 1.2.1.3 Surgical anesthesia Rats were anesthetized with Zotal at a dose of 0.4 ml / kg, injected into the outer thigh muscle. Rats fell asleep after approximately 3 minutes. Surgery could be started after confirming that the rats lost pain response and eyelid reflex.

[0056] 1.2.1.4 Surgical puncture The rats' backs were cleaned with a shaver. A circular wound with a diameter of 1.5 cm was then made in the center of the rats' backs using a circular punch. The maximum and minimum diameters of the wounds were measured and recorded using a vernier caliper. Finally, the wounds were photographed.

[0057] 1.2.1.5 Postoperative management Use commercially available ibuprofen syrup mixed with drinking water. Use a high dose (approximately 4.2 ml of syrup mixed with 500 ml of drinking water) for 3 days after surgery. Observe the rat daily. If the wound is healed, there is no irritability, no biting of the wound, and no arching of the back, the dose can be reduced to a low dose. If the opposite is true, continue to use the high dose for analgesia.

[0058] 1.2.2 Healing rate measurement method Wound diameters were measured on days 0, 3, 7, 11, 16, and 21. Rats were sedated with Zotal (0.3 ml / kg) intramuscularly in the lateral thigh. Approximately 5 minutes later, the rats fell asleep. The maximum and minimum wound diameters were measured and recorded using a vernier caliper. Finally, the wounds were photographed.

[0059] 2.1 Healing rate results The average of the maximum and minimum diameters of the rat wound was taken as the diameter of the circular wound of the rat, and the wound area of ​​the rat was calculated using the circle area formula (cm 2 ), healing rate = wound area on day X / wound area on day 0. The results are as follows Figure 1 shown.

[0060]

[0061]

[0062]

[0063] It can be seen from the above data that the wound healing speed of the rats in the formula group is faster than that of the erythromycin group, EGF group and negative group, which can prove that the healing agent of the present invention has a better promoting effect on wound healing than the commercially available erythromycin and medical recombinant type III humanized collagen repair gel.

[0064] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. A wound disinfectant and repairing agent containing modified chitosan, characterized in that The composition comprises, by mass percentage, 3-10% organic acid, 1-30% chitosan, 2-20% benzalkonium bromide, 1-10% liposome solution, and the balance being water.

2. The wound disinfecting and repairing agent containing modified chitosan according to claim 1, characterized in that: The organic acid is any one or more of formic acid, benzoic acid, acetic acid, propionic acid, butyric acid, succinic acid, valeric acid, tartaric acid, oxalic acid, ascorbic acid, malic acid, citric acid, lactic acid, salicylic acid, and caffeic acid.

3. A method for preparing a wound disinfecting and repairing agent containing modified chitosan according to claim 1 or 2, characterized in that The steps include: (1) Dissolve the organic acid in water to obtain an acidic solution; (2) Add chitosan to the acidic solution and stir at room temperature for 1-5 hours until completely homogenized; (3) preparing liposome solution by electric field-assisted liposome preparation; (4) Mix the liposome solution and chitosan solution, stir slowly at 20-80°C for 1-6 hours, add benzalkonium bromide during the process, and mix well; (5) Use a 100K ultrafiltration tube to separate the chitosan solution with a molecular weight greater than 100,000, and then re-dissolve it with physiological saline.

4. The method for preparing a wound disinfecting and repairing agent containing modified chitosan according to claim 3, characterized in that Step (3) specifically includes the following steps: (1) Dissolve phosphatidylcholine and cholesterol in a chloroform:methanol mixed solution to form a homogeneous liposome solution, then place the liposome solution in an evaporation tube container, and dry the liposome solution by rotary evaporation to form a thin film in the evaporation tube; (2) Add physiological saline to the evaporating tube and slowly stir at 37°C for 1-3 hours to redisperse the lipids into liposomes; (3) Placing the liposome suspension in an electric field device, using an AC electric field with electric field parameters of 1-100 kV / m, 1-500 kHz, and 1-100 minutes. Under the action of the electric field, the lipid molecules will rearrange to form multilamellar liposomes; (4) Emulsifying the multilayer liposome solution using an ultrasonic processor. The ultrasonic processor power needs to be between 100-1000 W, the frequency needs to be 1-100 kHz, and the process needs to be performed at room temperature for 1-5 hours. The purpose is to adjust the liposome particle size to the target range, which is 10-1000 nm. (5) Using dialysis for purification, the electric field-assisted liposome preparation is completed.

5. The method for preparing the wound disinfectant and repairing agent according to claim 4, characterized in that: In step (1), the mass percentage of phosphatidylcholine in the homogeneous liposome solution is 1-10%, the mass percentage of cholesterol is 2-20%, and the volume ratio of chloroform to methanol in the chloroform:methanol mixed solution is 2:

1.

6. The method for preparing the wound disinfectant and repairing agent according to claim 4, characterized in that: In step (2), the volume of the physiological saline added is the same as that of the chloroform:methanol mixed solution in step (1).

7. The method for preparing the wound disinfectant and repairing agent according to claim 4, characterized in that: In step (5), the dialysis is specifically as follows: the liposome solution is placed in a dialysis bag, and then 1000 times the volume of normal saline is added.

Images